A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.

about

Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat.Accuracy of the HumaSensplus point-of-care uric acid meter using capillary blood obtained by fingertip puncture.

P2860

Q42688139-C15DCB63-E72A-4253-8B1F-34BEE14B6565 Q55262503-30165544-F6FD-4A9F-A36C-EA0FE9AF60CE

P2860

A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.

Item

http://www.wikidata.org/entity/Q36302521

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.

@ast

A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.

@en

type

Item

label

A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.

@ast

A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.

@en

prefLabel

A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.

@ast

A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.

@en

P1476

A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.

@en

P2093

Aylin Altan

http://www.w3.org/2001/XMLSchema#string

Tim Bancroft

http://www.w3.org/2001/XMLSchema#string

P2860

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.

Serum urate levels and gout flares: analysis from managed care data.

Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout.

Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.

Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.

P304

411-418

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/RHU.0000000000000322

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Aki Shiozawa

Jasvinder A. Singh

P577

2015-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

284171573

http://www.w3.org/2001/XMLSchema#string

P698

26580304

http://www.w3.org/2001/XMLSchema#string

P932

4654265

http://www.w3.org/2001/XMLSchema#string

A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.

about

P2860

P2860

A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932